Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1144606 | 1.00 | MAPT (0.50) | MAPTMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL8227037 | 1.00 | MAPT (0.50) | MAPTMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL1143928 | 0.92 | MAPT (0.45) | MAPTMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL19203211 | 0.88 | ALDH1A1 (0.53) | MAPTNPC1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1144588 | 0.87 | LMNA (0.57) | MAPTMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL1144585 | 0.87 | LMNA (0.57) | MAPTMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL30189372 | 0.86 | MAPT (0.44) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL11393110 | 0.84 | PARP1 (0.53) | MAPTNPC1ALDH1A1RAB9AKDM4E | |
| SCHEMBL11393086 | 0.84 | PARP1 (0.53) | MAPTNPC1ALDH1A1RAB9AKDM4E | |
| SCHEMBL2891426 | 0.83 | KMT2A (0.44) | MAPTMEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7015348-B2 | Method for producing an optically active β-amino acid | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-03-21 | — | — | US | claimed |
| US-20220324814-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS INC (US) | 2022-10-13 | — | — | US | disclosed |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| CN-113444037-A | Green synthesis method of nicotinic acid ester compound based on nonmetal condition | 安阳师范学院 | 2021-09-28 | — | — | CN | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
| CN-108117516-B | Preparation method and application of polysubstituted pyridine derivative | 浙江工业大学 | 2021-01-19 | — | — | CN | disclosed |
| CN-107739332-B | Synthesis method of pyridine-3-formate compound | 河南师范大学 | 2020-02-21 | — | — | CN | disclosed |
| CN-110615762-A | Synthesis method of ethyl 2,4, 6-triphenylnicotinate | 浙江工业大学 | 2019-12-27 | — | — | CN | disclosed |
| US-5859244-A | EXHIBIT VASODILATING ACTIVITY BASED ON CALCIUM ANTAGONISM AND PLATELET-ACTIVATING FACTOR ANTAGONISM | FUJIREBIO, INC. (JP) | 1999-01-12 | — | — | US | disclosed |
| US-5763614-A | VASODILATION BASED ON CALCIUM ANTAGONISM AND PAF ANTAGONISM | FUJIREBIO INC. (JP) | 1998-06-09 | — | — | US | disclosed |
| US-5696268-A | REACTING N-ACYLAMINO ACID DERIVATIVE WITH OPTICALLY ACTIVE ENAMINE DERIVATIVE, REACTING PRODUCT WITH AMMONIA OR AMMONIUM SALT | FUJIREBIO INC. (JP) | 1997-12-09 | — | — | US | disclosed |
| US-5644059-A | REACTION OF KETONE WITH ACRYLAMIDE AND AMMONIA OR AMMONIUM SALT | FUJIREBIO INC. (JP) | 1997-07-01 | — | — | US | disclosed |
| US-5367081-A | Vasodilator, antiallergen | FUJIREBIO INC. (JP) | 1994-11-22 | — | — | US | disclosed |
| US-5198439-A | Hypotensive agents, congestive heart failure | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-03-30 | — | — | US | disclosed |
| US-5130318-A | Hypotensive agents and for treatment of congestive heart failure | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-07-14 | — | — | US | disclosed |
| EP-0488345-A1 | 1,4-Dihydropyridine derivatives and methods of producing the same | FUJIREBIO INC. (JP) | 1992-06-03 | — | — | EP | disclosed |
| EP-0453210-A2 | Pyridine derivatives | ZENECA LIMITED (GB) | 1991-10-23 | — | — | EP | disclosed |
| US-4358606-A | Esters of phenalkyloxycarbonylamino acids | ZOECON CORPORATION (US) | 1982-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | MAPT 562/4885MEN1 4845/4885KMT2A 4418/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | MAPT 330/4885MEN1 4832/4885KMT2A 4469/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | MAPT 562/4885MEN1 4845/4885KMT2A 4418/4885 |
| US-20220324814-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | MAPT 562/4885MEN1 4845/4885KMT2A 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.